1
|
Sommariva S, Caviglia G, Ravera S, Frassoni F, Benvenuto F, Tortolina L, Castagnino N, Parodi S, Piana M. Computational quantification of global effects induced by mutations and drugs in signaling networks of colorectal cancer cells. Sci Rep 2021; 11:19602. [PMID: 34599254 PMCID: PMC8486743 DOI: 10.1038/s41598-021-99073-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 09/13/2021] [Indexed: 11/09/2022] Open
Abstract
Colorectal cancer (CRC) is one of the most deadly and commonly diagnosed tumors worldwide. Several genes are involved in its development and progression. The most frequent mutations concern APC, KRAS, SMAD4, and TP53 genes, suggesting that CRC relies on the concomitant alteration of the related pathways. However, with classic molecular approaches, it is not easy to simultaneously analyze the interconnections between these pathways. To overcome this limitation, recently these pathways have been included in a huge chemical reaction network (CRN) describing how information sensed from the environment by growth factors is processed by healthy colorectal cells. Starting from this CRN, we propose a computational model which simulates the effects induced by single or multiple concurrent mutations on the global signaling network. The model has been tested in three scenarios. First, we have quantified the changes induced on the concentration of the proteins of the network by a mutation in APC, KRAS, SMAD4, or TP53. Second, we have computed the changes in the concentration of p53 induced by up to two concurrent mutations affecting proteins upstreams in the network. Third, we have considered a mutated cell affected by a gain of function of KRAS, and we have simulated the action of Dabrafenib, showing that the proposed model can be used to determine the most effective amount of drug to be delivered to the cell. In general, the proposed approach displays several advantages, in that it allows to quantify the alteration in the concentration of the proteins resulting from a single or multiple given mutations. Moreover, simulations of the global signaling network of CRC may be used to identify new therapeutic targets, or to disclose unexpected interactions between the involved pathways.
Collapse
Affiliation(s)
- Sara Sommariva
- Dipartimento di Matematica, Università di Genova, via Dodecaneso 35, 16146, Genoa, Italy.
| | - Giacomo Caviglia
- Dipartimento di Matematica, Università di Genova, via Dodecaneso 35, 16146, Genoa, Italy
| | - Silvia Ravera
- Dipartimento di Medicina Sperimentale, Università di Genova, Via De Toni 14, 16132, Genoa, Italy
| | - Francesco Frassoni
- Dipartimento di Matematica, Università di Genova, via Dodecaneso 35, 16146, Genoa, Italy
| | - Federico Benvenuto
- Dipartimento di Matematica, Università di Genova, via Dodecaneso 35, 16146, Genoa, Italy
| | - Lorenzo Tortolina
- Dipartimento di Medicina Interna, Università di Genova, via Leon Battista Alberti 2, 16132, Genoa, Italy
| | - Nicoletta Castagnino
- Dipartimento di Medicina Interna, Università di Genova, via Leon Battista Alberti 2, 16132, Genoa, Italy
| | - Silvio Parodi
- Dipartimento di Medicina Interna, Università di Genova, via Leon Battista Alberti 2, 16132, Genoa, Italy
| | - Michele Piana
- Dipartimento di Matematica, Università di Genova, via Dodecaneso 35, 16146, Genoa, Italy
| |
Collapse
|
2
|
Yang H, Zhang J, Li J, Zhao F, Shen Y, Xing X. Overexpression of miR-574-3p suppresses proliferation and induces apoptosis of chronic myeloid leukemia cells via targeting IL6/JAK/STAT3 pathway. Exp Ther Med 2018; 16:4296-4302. [PMID: 30344703 DOI: 10.3892/etm.2018.6700] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Accepted: 08/23/2018] [Indexed: 12/16/2022] Open
Abstract
The present study aimed to elucidate the potential roles and regulatory mechanism of microRNA (miR)-574-3p in the development of chronic myeloid leukemia (CML). The expression of miR-574-3p in peripheral blood obtained from patients with CML was examined. Subsequently, miR-574-3p was overexpressed and suppressed in CML K562 cells to further investigate the effects of miR-574-3p on cell proliferation, and apoptosis. Furthermore, a luciferase reporter assay was performed to investigate whether interleukin-6 (IL-6) was a target of miR-574-3p. In addition, the regulatory association between miR-574-3p and the IL-6/Janus kinase (JNK)/signal transducer and activator of transcription-3 (STAT3) signaling pathway was explored. The expression of miR-574-3p in the peripheral blood obtained from patients with CML was significantly lower compared with that in healthy controls. Overexpression of miR-574-3p significantly inhibited the proliferation and induced the apoptosis of K562 cells, whereas suppression of miR-574-3p exhibited opposite effects. In addition, IL-6 was identified to be a direct target of miR-574-3p. Overexpression of IL-6 significantly promoted the proliferation and inhibited the apoptosis of K562 cells. Furthermore, overexpression of miR-574-3p inhibited the activation of the JAK/STAT3 signaling pathway, which was rescued by overexpression of IL-6. The results of the current study indicate that miR-574-3p overexpression may serve an important role in inhibiting proliferation and inducing apoptosis of K562 cells via suppression of IL-6/JAK/STAT3 signaling pathway activation. miR-574-3p may serve as a potential therapeutic target for CML.
Collapse
Affiliation(s)
- Haoying Yang
- Department of Blood Transfusion, San Er Ling Yi Hospital Affiliated to School of Medicine, Xi'an Jiaotong University, Hanzhong, Shanxi 723000, P.R. China
| | - Jun Zhang
- Department of Clinical Laboratory, San Er Ling Yi Hospital Affiliated to School of Medicine, Xi'an Jiaotong University, Hanzhong, Shanxi 723000, P.R. China
| | - Jiuping Li
- Department of Blood Transfusion, San Er Ling Yi Hospital Affiliated to School of Medicine, Xi'an Jiaotong University, Hanzhong, Shanxi 723000, P.R. China
| | - Furong Zhao
- Department of Blood Transfusion, San Er Ling Yi Hospital Affiliated to School of Medicine, Xi'an Jiaotong University, Hanzhong, Shanxi 723000, P.R. China
| | - Yao Shen
- Department of Clinical Laboratory, San Er Ling Yi Hospital Affiliated to School of Medicine, Xi'an Jiaotong University, Hanzhong, Shanxi 723000, P.R. China
| | - Xuemei Xing
- Department of Clinical Laboratory, San Er Ling Yi Hospital Affiliated to School of Medicine, Xi'an Jiaotong University, Hanzhong, Shanxi 723000, P.R. China
| |
Collapse
|
3
|
Panuzzo C, Volpe G, Cibrario Rocchietti E, Casnici C, Crotta K, Crivellaro S, Carrà G, Lorenzatti R, Peracino B, Torti D, Morotti A, Camacho-Leal MP, Defilippi P, Marelli O, Saglio G. New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia. Oncoscience 2015; 2:880-91. [PMID: 26682280 PMCID: PMC4671955 DOI: 10.18632/oncoscience.260] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 11/09/2015] [Indexed: 12/15/2022] Open
Abstract
In Chronic Myeloid Leukemia 80% of patients present alternative splice variants involving BCR exons 1, 13 or 14 and ABL exon 4, with a consequent impairment in the reading frame of the ABL gene. Therefore BCR/ABL fusion proteins (BCR/ABL-OOF) are characterized by an in-frame BCR portion followed by an amino acids sequence arising from the out of frame (OOF) reading of the ABL gene. The product of this new transcript contains the characteristic BCR domains while lacking the COOH-terminal Rho GTPase GAP domain. The present work aims to characterize the protein functionality in terms of cytoskeleton (re-)modelling, adhesion and activation of canonical oncogenic signalling pathways. Here, we show that BCR/ABL-OOF has a peculiar endosomal localization which affects EGF receptor activation and turnover. Moreover, we demonstrate that BCR/ABL-OOF expression leads to aberrant cellular adhesion due to the activation of Rac GTPase, increase in cellular proliferation, migration and survival. When overexpressed in a BCR/ABL positive cell line, BCR/ABL-OOF induces hyperactivation of Rac signaling axis offering a therapeutic window for Rac-targeted therapy. Our data support a critical role of BCR/ABL-OOF in leukemogenesis and identify a subset of patients that may benefit from Rac-targeted therapies.
Collapse
Affiliation(s)
- Cristina Panuzzo
- Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
| | - Gisella Volpe
- Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
| | | | - Claudia Casnici
- Department of Medical Biotechnologies and Translational Medicine, School of Medicine, University of Milan, Milan, Italy
| | - Katia Crotta
- Department of Medical Biotechnologies and Translational Medicine, School of Medicine, University of Milan, Milan, Italy
| | - Sabrina Crivellaro
- Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
| | - Giovanna Carrà
- Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
| | - Roberta Lorenzatti
- Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
| | - Barbara Peracino
- Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
| | - Davide Torti
- Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
| | - Alessandro Morotti
- Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
| | | | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Ornella Marelli
- Department of Medical Biotechnologies and Translational Medicine, School of Medicine, University of Milan, Milan, Italy
| | - Giuseppe Saglio
- Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
| |
Collapse
|